CHAPEL HILL, N.C., May 26, 2017 /PRNewswire/ -- Scientific publications remain the principal way that biopharmaceutical organizations relay critical clinical trial data to key external stakeholders such as physicians and payers. Data from different phases of drug development are the earliest ways these stakeholders learn about new products and the information serves as the building blocks for how a new product will be positioned in the marketplace.
With growing calls for transparency and data disclosure, global publications leaders find themselves in a balancing act—ensuring both scientific credibility and commercial viability. To help publications leaders navigate this emerging landscape, research and consulting leader Best Practices, LLC undertook benchmarking research to investigate how top pharmaceutical and biotechnology companies shape their global scientific publication strategies to maintain credibility in the scientific community and deliver publications that drive brand success.
The study found that open access platforms are gaining popularity for publication processes; 44% of companies in the study believe such platforms will impact publication strategy going forward. Part of the allure for open access platforms is they make information readily available to physicians and patients alike. In the wake of open access platforms, companies foresee an impact on areas such as journal selection, publication approval and delivery, and speed of data disclosure.
In particular, this study provides benchmarks around publications structure and leadership; staffing and budget levels; publication strategy creation and data delivery; publication channel utilization across product lifecycle; and measuring publication effectiveness. In addition, the 85-page study identifies publication strategy changes for the new marketplace, best practices for maximizing the effectiveness of strategic publication planning, top publication challenges and lessons learned for implementing successful scientific publication strategy.
"Best Practices in Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance" will help publication leaders better understand how an effective publications strategy can boost an organization's scientific credibility and a new product's commercial viability.
Key topics in the study include:
- Optimal structure for the global publications function
- Transition of global publications from commercial to clinical
- Key internal stakeholders who contribute to publications strategy
- Tactics for handling publication of neutral or negative clinical trial results
- Impact of transparency guidelines on publications, planning and delivery
- Strategy changes for the new marketplace
For this study, Best Practices, LLC engaged 20 leaders from 19 biopharmaceutical companies through a benchmarking survey and executive interviews.
To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1449.htm.
For related research, visit the Best Practices, LLC Web site at www.best-in-class.com/.
ABOUT BEST PRACTICES, LLC
Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.
SOURCE Best Practices, LLC